These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10952473)

  • 21. A systematic review to evaluate the effectiveness of carnitine supplementation in improving walking performance among individuals with intermittent claudication.
    Delaney CL; Spark JI; Thomas J; Wong YT; Chan LT; Miller MD
    Atherosclerosis; 2013 Jul; 229(1):1-9. PubMed ID: 23557982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment of intermittent claudication of the lower limbs.
    Chacón-Quevedo A; Eguaras MG; Calleja F; Garcia MA; Roman M; Casares J; Muñoz I; Concha M
    Angiology; 1994 Jul; 45(7):647-53. PubMed ID: 8024164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Naftidrofuryl in arterial obstructive disease: A systematic revue of the literature].
    Bourrion B; Hazard A; Baltazard H; Sebbag P; Fournier L; François M
    Rev Med Interne; 2020 Feb; 41(2):89-97. PubMed ID: 31669163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The limits of evidence in drug approval and availability: a case study of cilostazol and naftidrofuryl for the treatment of intermittent claudication.
    Hong H; Mackey WC
    Clin Ther; 2014 Aug; 36(8):1290-301. PubMed ID: 25012728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naftidrofuryl: a review of its use in the treatment of intermittent claudication.
    Goldsmith DR; Wellington K
    Drugs Aging; 2005; 22(11):967-77. PubMed ID: 16323973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis of randomized, double-blind, placebo-controlled studies of the effect of buflomedil on intermittent claudication.
    Walker GA; Mac Hannaford JC
    Fundam Clin Pharmacol; 1995; 9(4):387-94. PubMed ID: 8566940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatment options in intermittent claudication: the US experience.
    Hiatt WR
    Int J Clin Pract Suppl; 2001 Apr; (119):20-7. PubMed ID: 11355276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of naftidrofuryl in patients with intermittent claudication.
    Karnik R; Valentin A; Stöllberger C; Slany J
    Angiology; 1988 Mar; 39(3 Pt 1):234-40. PubMed ID: 3281516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Authors' reply: systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2013 Dec; 100(13):1838-9. PubMed ID: 24227373
    [No Abstract]   [Full Text] [Related]  

  • 30. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication (Br J Surg 2012; 99: 1630-1638).
    Roset PN
    Br J Surg; 2013 Dec; 100(13):1838. PubMed ID: 24227374
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication].
    Boccalon H; Lehert P; Mosnier M
    Ann Cardiol Angeiol (Paris); 2001 Apr; 50(3):175-82. PubMed ID: 12555510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
    Kieffer E; Bahnini A; Mouren X; Gamand S
    Int Angiol; 2001 Mar; 20(1):58-65. PubMed ID: 11342997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous naftidrofuryl for critical limb ischaemia.
    Smith FB; Bradbury AW; Fowkes FG
    Cochrane Database Syst Rev; 2000; (2):CD002070. PubMed ID: 10796677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vasoactive drugs in peripheral arterial perfusion disorders. Problems, principles and results of the determination of therapeutic efficacy].
    Heidrich H
    Dtsch Med Wochenschr; 1985 Aug; 110(31-32):1219-24. PubMed ID: 3926447
    [No Abstract]   [Full Text] [Related]  

  • 35. Bias in benefit-risk appraisal in older products: the case of buflomedil for intermittent claudication.
    De Backer TL; Vander Stichele RH; Van Bortel LM
    Drug Saf; 2009; 32(4):283-91. PubMed ID: 19388720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    ; Leizorovicz A; Becker F
    Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Naftidrofuryl for acute stroke.
    Leonardi-Bee J; Steiner T; Bath-Hextall F
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005478. PubMed ID: 17443593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous naftidrofuryl for critical limb ischaemia.
    Smith FB; Bradbury A; Fowkes G
    Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD002070. PubMed ID: 22786478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of the effectiveness of intra-arterial and intravenous administration of buflomedil in patients with intermittent claudication].
    Diehm C; Eckstein M; Hübsch-Müller C
    Vasa; 1989; 18(1):40-7. PubMed ID: 2648691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.
    Moody AP; al-Khaffaf HS; Lehert P; Harris PL; Charlesworth D
    J Cardiovasc Pharmacol; 1994; 23 Suppl 3():S44-7. PubMed ID: 7517477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.